Inhibitors targeting the SF3B complex or its SF3B1 subunit can precisely calibrate the constitutive or selective splicing of precursor mRNA by altering the ability of SF3B1 and PHF5A to recognize different intron branch point sequences, thereby exerting anti-tumor activity (Larsen, 2021; Yamauchi et al., 2022). This evidence concerns the gene SF3B1 and neoplasm.